At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 190 enrolled
Drug / intervention
LY686017 +1 moredrug
Likely dose
LY686017 50 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of LY686017 Compared With Placebo for the Treatment of Alcohol Dependence
In Brief
A Phase 2 clinical trial evaluating LY686017 and Placebo for Alcohol Dependence. Completed, enrolled 190 participants across 21 sites.
Detailed Summary
H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with placebo in a 12-week trial that includes Medical Management. This study is an outpatient study in which approximately 180 alcohol dependent subjects will be enrolled. Subjects will be randomized in a 1:1 fashion to LY686017 or placebo, and will receive once daily dosing for twelve weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Dependence
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedDec 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedDec 9, 2008
Enrollment StartDec 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.6 years ago
Interventions
LY686017drug
50 milligrams (mg) daily by oral route for 12 weeks
Placebodrug
Daily by oral route for 12 weeks